CTI BioPharma Corp. (CTIC)

Market Cap	660.00M
Revenue (ttm)	14.62M
Net Income (ttm)	-120.80M
Shares Out	114.39M
EPS (ttm)	-1.23
PE Ratio	n/a
Forward PE	26.60
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,840,526
Open	5.73
Previous Close	5.64
Day's Range	5.56 - 5.78
52-Week Range	1.43 - 7.80
Beta	0.88
Analysts	Buy
Price Target	10.95 (+89.8%)
Earnings Date	Nov 10, 2022

About CTIC

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed ...

• Industry: Biotechnology
• IPO Date: Mar 21, 1997
• CEO: Adam Craig
• Employees: 121
• Stock Exchange: NASDAQ
• Ticker Symbol: CTIC

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CTIC stock is "Buy." The 12-month stock price forecast is 10.95, which is an increase of 89.77% from the latest price.

Price Target

$10.95

(89.77% upside)

Analyst Consensus: Buy

Stock Forecasts